Search

State

Industry

Company

PHARMACEUTICAL PREPARATIONS

Development Agreement

Acadia Pharmaceuticals Inc

DEVELOPMENT AGREEMENT Development Agreement Certain confidential information contained in this document, marked by brackets and asterisks, has been omitted pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406, and has been filed separately with the Securities and Exchange Commission DEVELOPMENT AGREEMENT THIS DEVELOPMENT AGREEMENT (this “

SERVICES-MOTION PICTURE & VIDEO TAPE PRODUCTION

Development Agreement

Douglas Emmett Inc

DIGITAL LIKENESS DEVELOPMENT AGREEMENT THIS DIGITAL LIKENESS DEVELOPMENT AGREEMENT (this Agreement) is made and entered into as of July 31, 2019 (the Effective Date) between PULSE Evolution Group, Inc., a Florida corporation (PULSE), FaceBank, Inc., a Florida corporation (FaceBank), and Floyd Mayweather, an individual, represented by ONE Entertainment (Mayweather). WHEREAS, PULSE is a gl

SEMICONDUCTORS & RELATED DEVICES

ADDENDUM TO DEVELOPMENT AGREEMENT

Microchip Technology Inc

ADDENDUM TO DEVELOPMENT AGREEMENT CONTRACT C2000-104 ORIGINAL CONTRACT NO. C97-141 ADDENDUM TO DEVELOPMENT AGREEMENT BETWEEN CITY OF TEMPE AND MICROCHIP TECHNOLOGY INC. ADDENDUM TO DEVELOPMENT AGREEMENT C2000-104 Original C97-141 This Addendum to Development Agreement C97-141 is made the 11th day of May, 2000 by and between the City of Tempe, Arizona, an Arizona municipal corporation ("Tempe" or "

RETAIL-EATING & DRINKING PLACES

1 DEVELOPMENT AGREEMENT ADDENDUM THIS DEVELOPMENT

Starbucks Corp

.3 1 DEVELOPMENT AGREEMENT ADDENDUM THIS DEVELOPMENT AGREEMENT ADDENDUM (the "Addendum") is entered into as of April 16, 1998, between Starbucks Corporation ("Starbucks") and Host International, Inc. ("Licensee"). RECITALS: WHEREAS, Licensee and Starbucks are parties to that certain development agreement dated March 1994, as amended (the "Development Agreement"); and WHEREAS, the parties have dev

PHARMACEUTICAL PREPARATIONS

AMENDED AND RESTATED DISCOVERY AND PRECLINICAL

Regeneron Pharmaceuticals, Inc.

AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT exhibit10-14.htm Portions of this Have Been Omitted and Separately Filed with the Securities and Exchange Commission with a Request for Confidential Treatment AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT By and Between AVENTIS PHARMACEUTICALS INC. and REGENERON PHARMACEUTICALS, INC. Dated as of November 10

RETAIL-EATING & DRINKING PLACES

1 DEVELOPMENT AGREEMENT ADDENDUM THIS DEVELOPMENT

Starbucks Corp

.2 1 DEVELOPMENT AGREEMENT ADDENDUM THIS DEVELOPMENT AGREEMENT ADDENDUM (the "Addendum") is entered into as of March 2, 1998, between Starbucks Corporation ("Starbucks") and Host International, Inc. ("Licensee"). RECITALS: WHEREAS, Licensee and Starbucks are parties to that certain development agreement dated March 1994, as amended (the "Development Agreement"); and WHEREAS, the parties have deve

PHARMACEUTICAL PREPARATIONS

Development Agreement

Acadia Pharmaceuticals Inc

DEVELOPMENT AGREEMENT Development Agreement Certain confidential information contained in this document, marked by brackets and asterisks, has been omitted pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406, and has been filed separately with the Securities and Exchange Commission DEVELOPMENT AGREEMENT THIS DEVELOPMENT AGREEMENT (this “

PHARMACEUTICAL PREPARATIONS

LICENSE AND DEVELOPMENT AGREEMENT

Acura Pharmaceuticals, Inc

LICENSE AND DEVELOPMENT AGREEMENT This License and Development Agreement (“Agreement”) is made and entered into as of this June 5, 2015 (the “Effective Date”) by and between Bayer HealthCare LLC, with offices at 100 Bayer Blvd., Whippany, NJ 07981 (“Bayer”), and Acura Pharmaceuticals, Inc., with offices at 616 N. North Court, Palatine IL 60067 (“Acura”). Bayer and Acura each are referred to herei

SEMICONDUCTORS & RELATED DEVICES

"S" Process Development Agreement

Advanced Micro Devices Inc

"S" PROCESS DEVELOPMENT AGREEMENT "S" Process Development Agreement *** Confidential treatment has been requested as to certain portions of this agreement. Such omitted confidential information has been designated by an asterisk and has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, and the Commission’

PHARMACEUTICAL PREPARATIONS

IO DISCOVERY AND DEVELOPMENT AGREEMENT BY

Regeneron Pharmaceuticals, Inc.

IO DISCOVERY AND DEVELOPMENT AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI Document IMMUNO-ONCOLOGY DISCOVERY AND DEVELOPMENT AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Dated as of July 1, 2015 CERTAIN PORTIONS OF THIS HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIALITY. SUCH OMITTED PORTIONS, WHICH ARE MARKED WITH BRACKETS AND THREE ASTERISK